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SCIENTIFIC OPINION  
Scientific Opinion on Flavouring Group Evaluation 30, Revision 1 
(FGE.30Rev1): 
4-Prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-
methylbutyrate from chemical group 171 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)2, 3  
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT 
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European 
Food Safety Authority was requested to evaluate two flavouring substances in the Flavouring Group 
Evaluation 30, Revision 1, using the Procedure in Commission Regulation (EC) No 1565/2000. None 
of the substances were considered to have genotoxic potential. The two substances were evaluated 
through a stepwise approach that integrates information on structure-activity relationships, intake from 
current uses, toxicological threshold of concern, and available data on metabolism and toxicity. The 
Panel concluded that the two substances [FL-no: 04.097, 09.894] do not give rise to safety concerns at 
their levels of dietary intake, estimated on the basis of the MSDI approach. Besides the safety 
assessment of these flavouring substances, the specifications for the materials of commerce have also 
been considered. For [FL-no: 09.894] the composition of the stereoisomeric mixture needs to been 
specified.  
 
© European Food Safety Authority, 2011 
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SUMMARY 
The European Food Safety Authority (EFSA) asked the Panel on Food Contact Materials, Enzymes, 
Flavourings and Processing Aids (the Panel) to provide scientific advice to the Commission on the 
implications for human health of chemically defined flavouring substances used in or on foodstuffs in 
the Member States. In particular, the Panel was requested to evaluate two flavouring substances in the 
Flavouring Group Evaluation 30, Revision 1 (FGE.30Rev1), using the Procedure as referred to in the 
Commission Regulation (EC) No 1565/2000. The flavouring substances belong to chemical group 17, 
Annex I of the Commission Regulation (EC) No 1565/2000. 
The two flavouring substances are a hydroxypropenylbenzene, 4-prop-1-enylphenol [FL-no: 04.097], 
and a structurally related ester,  2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate[FL-no: 09.894], 
both from chemical group 17. 
Due to the presence and the position of a double bond both flavouring substances can exist as 
geometrical isomers. For 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate the stereoisomeric 
composition has been specified as the E/Z mixture, but the composition of the mixture has not been 
given.  
4-Prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate are classified into 
structural class I.  
The candidate substances have been reported to occur naturally in anise oil and cider. 
According to the default MSDI approach, the flavouring substances in this group have European 
intakes of 0.012 and 12 microgram/capita/day ([FL-no: 09.894 and 04.097], respectively), which are 
below the threshold of concern for structural class I substances of 1800 microgram/person/day. 
On the basis of the reported annual production in Europe (MSDI approach) the total combined intake 
of the two flavouring substances and six structurally related substances from structural class I can be 
calculated to approximately 150 microgram/capita/day. This value is lower than the threshold of 
concern for structural class I substances of 1800 microgram/person/day. 
Data available do not give rise to safety concern with respect to genotoxicity. 
4-Prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate are expected to be 
metabolised to innocuous products. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present Flavouring Group Evaluation. The Panel considered that elicitation of tumours by the 
supporting substance isoeugenol in rodents is connected to a non genotoxic mechanism. Therefore, the 
candidate substances [FL-no: 04.097 and 09.894] can be evaluated via a threshold based approach, i.e. 
the Procedure. 
It is considered that on the basis of the default MSDI approach the candidate substances would not 
give rise to safety concern at the estimated levels of intake arising from use as flavouring substances. 
When the estimated intake was based on the mTAMDI approach it was 72 and 2300 
microgram/person/day for 4-prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-
methylbutyrate, respectively. For 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate this intake 
estimate is above the threshold of concern for structural class I substances of 1800 
microgram/person/day, and therefore,  more reliable exposure data are required for this substance. On 
the basis of such additional data, the flavouring substance should be reconsidered along the steps of 
the Procedure. Following this procedure additional toxicological data might become necessary. 4-
Prop-1-enylphenol, for which the estimated intake is below the threshold, is also expected to be 
metabolised to innocuous products. 
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In order to determine whether the conclusion for the two flavouring substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications, including complete purity criteria and identity, have been given for 4-prop-1-
enylphenol [FL-no: 04.097] and 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate [FL-no: 09.894], 
except that information on the composition of the stereoisomeric mixture has not been specified for 
[FL-no: 09.894]. Thus, the final evaluation of the material of commerce cannot be performed for [FL-
no: 09.894], pending further information.  
For 4-prop-1-enylphenol [FL-no: 04.097] the Panel concluded that it would present no safety concern 
at the estimated level of intake based on the MSDI approach. 
 
KEYWORDS 
Flavourings, safety, phenolic ester, propenylhydrobenzenes, FGE.30.  
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BACKGROUND 
Regulation (EC) No 2232/96 of the European Parliament and the Council (EC, 1996a) lays down a 
Procedure for the establishment of a list of flavouring substances the use of which will be authorised 
to the exclusion of all other substances in the EU. In application of that Regulation, a Register of 
flavouring substances used in or on foodstuffs in the Member States was adopted by Commission 
Decision 1999/217/EC (EC, 1999a), as last amended by Commission Decision 2009/163/EC (EC, 
2009a). Each flavouring substance is attributed a FLAVIS-number (FL-number) and all substances are 
divided into 34 chemical groups. Substances within a group should have some metabolic and 
biological behaviour in common. 
Substances which are listed in the Register are to be evaluated according to the evaluation programme 
laid down in Commission Regulation (EC) No 1565/2000 (EC, 2000a), which is broadly based on the 
Opinion of the Scientific Committee on Food (SCF, 1999a). For the submission of data by the 
manufacturer, deadlines have been established by Commission Regulation (EC) No 622/2002 (EC, 
2002b).  
After the completion of the evaluation programme the Union List of flavouring substances for use in 
or on foods in the EU shall be adopted (Article 5 (1) of Regulation (EC) No 2232/96) (EC, 1996a). 
TERMS OF REFERENCE 
The European Food Safety Authority (EFSA) is requested to carry out a risk assessment on flavouring 
substances in the Register prior to their authorisation and inclusion in a Union List according to 
Commission Regulation (EC) No 1565/2000 (EC, 2000a). In addition, the Commission requested 
EFSA to evaluate newly notified flavouring substances, where possible, before finalising the 
evaluation programme. 
HISTORY OF THE EVALUATION  
FGE Opinion 
Adopted by 
EFSA 
Link No. of 
Candidate 
Substances 
FGE.30 January 2010 http://www.efsa.europa.eu/en/scdocs/scdoc/1787.htm 1 
FGE.30Rev1 February 2011  2 
 
The present revision of Flavouring Group Evaluation 30, Revision 1 (FGE.30Rev1), includes the 
assessment of one additional candidate substance [FL-no: 04.097]. No toxicity and/or metabolism data 
were provided for this substance. A search in open literature did not provide any further data on 
toxicity or metabolism. 
ASSESSMENT 
1. Presentation of the Substances in Flavouring Group Evaluation 30 
1.1. Description 
The present Flavouring Group Evaluation 30, Revision 1 (FGE.30Rev1), using the Procedure as 
referred to in the Commission Regulation (EC) No 1565/2000 (EC, 2000a) (The Procedure – shown in 
schematic form in Annex I of this FGE), deals with a hydroxypropenylbenzene, 4-prop-1-enylphenol 
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and a structurally related ester,  2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate, both from 
chemical group 17, Annex I of Commission Regulation (EC) No 1565/2000 (EC, 2000a). 
The flavouring substances under consideration, 4-prop-1-enylphenol [FL-no: 04.097] and 2-methoxy-
4-(prop-1-enyl)phenyl 3-methylbutyrate [FL-no: 09.894], as well as their FLAVIS- ( FL-), Chemical 
Abstract Service- (CAS-), Council of Europe- (CoE-) and Flavor and Extract Manufactures 
Association- (FEMA-) numbers, structures and specifications, are listed in Table 1. 
A summary of the safety evaluation is summarised in Table 2a. 
The flavouring substances (candidate substances) are closely related structurally to six flavouring 
substances (supporting substances) evaluated at the 61st JECFA meeting (JECFA, 2004a) in the group 
of “Hydroxypropenylbenzenes”. The supporting substances, with the respective structural formulas, 
FEMA, CoE, and CAS register numbers, evaluation status by Scientific Committee on Food (SCF), 
the JECFA, and by the CoE and the MSDI values, are listed in Table 3. 
The hydrolysis products of the candidate ester are listed in Table 2b. 
1.2. Stereoisomers 
It is recognised that geometrical and optical isomers of substances may have different properties. Their 
flavour may be different, they may have different chemical properties resulting in possible variability 
in their absorption, distribution, metabolism, elimination and toxicity. Thus information must be 
provided on the configuration of the flavouring substance, i.e. whether it is one of the 
geometrical/optical isomers, or a defined mixture of stereoisomers. The available specifications of 
purity will be considered in order to determine whether the safety evaluation carried out for candidate 
substances for which stereoisomers may exist can be applied to the material of commerce. Flavouring 
substances with different configurations should have individual chemical names and codes (CAS 
number, FLAVIS number etc.). 
Due to the presence and the position of a double bond both candidate substances can exist as 
geometrical isomers. For one of the substances [FL-no: 09.894], Industry has stated that it exists as a 
“mixture of isomers” (EFFA, 2010a). However, the Panel does not consider this information sufficient 
and requests data on the actual ratio. 
1.3. Natural Occurrence in Food 
2-Methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate [FL-no: 09.894] has been reported to occur in 
anise and  4-prop-1-enylphenol [FL-no: 04.097] has been reported to occur in cider (0.2 mg/kg) (TNO, 
2000; TNO, 2010).  
2. Specifications 
Purity criteria for the substances have been provided by the Flavouring Industry (EFFA, 2004ae; 
Flavour Industry, 2007m) (Table 1). 
Judged against the requirements in Annex II of Commission Regulation (EC) No 1565/2000 (EC, 
2000) this information is adequate for [FL-no: 04.097]. However, information on the composition of 
the mixture of geometrical isomers is missing for [FL-no: 09.894] (see Section 1.2 and Table 1). 
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3. Intake Data 
Annual production volumes of the flavouring substances as surveyed by the Industry can be used to 
calculate the “Maximised Survey-derived Daily Intake” (MSDI) by assuming that the production 
figure only represents 60 % of the use in food due to underreporting and that 10 % of the total EU 
population are consumers (SCF, 1999a). 
However, the Panel noted that due to year-to-year variability in production volumes, to uncertainties 
in the underreporting correction factor and to uncertainties in the percentage of consumers, the 
reliability of intake estimates on the basis of the MSDI approach is difficult to assess. 
The Panel also noted that in contrast to the generally low per capita intake figures estimated on the 
basis of this MSDI approach, in some cases the regular consumption of products flavoured at use 
levels reported by the Flavour Industry in the submissions would result in much higher intakes. In 
such cases, the human exposure thresholds below which exposures are not considered to present a 
safety concern might be exceeded. 
Considering that the MSDI model may underestimate the intake of flavouring substances by certain 
groups of consumers, the SCF recommended also taking into account the results of other intake 
assessments (SCF, 1999a). 
One of the alternatives is the “Theoretical Added Maximum Daily Intake” (TAMDI) approach, which 
is calculated on the basis of standard portions and upper use levels (SCF, 1995) for flavourable 
beverages and foods in general, with exceptional levels for particular foods. This method is regarded 
as a conservative estimate of the actual intake by most consumers because it is based on the 
assumption that the consumer regularly eats and drinks several food products containing the same 
flavouring substance at the upper use level. 
One option to modify the TAMDI approach is to base the calculation on normal rather than upper use 
levels of the flavouring substances. This modified approach is less conservative (e.g., it may 
underestimate the intake of consumers being loyal to products flavoured at the maximum use levels 
reported) (EC, 2000a). However, it is considered as a suitable tool to screen and prioritise the 
flavouring substances according to the need for refined intake data (EFSA, 2004a). 
3.1. Estimated Daily per Capita Intake (MSDI Approach) 
The intake estimation is based on the Maximised Survey-derived Daily Intake (MSDI) approach, 
which involves the acquisition of data on the amounts used in food as flavourings (SCF, 1999a). These 
data are derived from surveys on annual production volumes in Europe. These surveys were conducted 
in 1995 by the International Organization of the Flavour Industry, in which flavour manufacturers 
reported the total amount of each flavouring substance incorporated into food sold in the EU during 
the previous year (IOFI, 1995). The intake approach does not consider the possible natural occurrence 
in food. 
Average per capita intake (MSDI) is estimated on the assumption that the amount added to food is 
consumed by 10 % of the population4 (Eurostat, 1998). This is derived for candidate substances from 
estimates of annual volume of production provided by Industry and incorporates a correction factor of 
0.6 to allow for incomplete reporting (60 %) in the Industry surveys (SCF, 1999a). 
The annual production volumes of 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate [FL-no: 
09.894] and 4-prop-1-enylphenol [FL-no: 04.097] for use as flavouring substances in Europe are 
                                                     
 
4 EU figure 375 millions. This figure relates to EU population at the time for which production data are 
available, and is consistent (comparable) with evaluations conducted prior to the enlargement of the EU. No 
production data are available for the enlarged EU. 
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reported to be 0.1 kg and 100 kg, respectively (EFFA, 2004ae; Flavour Industry, 2007m), and the 
corresponding daily per capita intakes are  0.012 microgram and 12 microgram (Table 2a). 
3.2. Intake Estimated on the Basis of the Modified TAMDI (mTAMDI) 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values 
is based on the approach used by SCF up to 1995 (SCF, 1995). 
The assumption is that a person may consume a certain amount of flavourable foods and beverages per 
day. 
For the present evaluation of the candidate substances, information on food categories and normal and 
maximum use levels5,6,7 were submitted by the Flavour Industry (EFFA, 2004ae; EFFA, 2007a; 
Flavour Industry, 2007m). The candidate substances are used in flavoured food products divided into 
the food categories, outlined in Annex III of the Commission Regulation (EC) No 1565/2000 (EC, 
2000a), as shown in Table 3.1. For the present calculation of mTAMDI, the reported normal use levels 
were used. In the case where different use levels were reported for different food categories the highest 
reported normal use level was used. 
According to the Flavour Industry the normal use levels for the candidate substances are in the range 
of 0.1 - 20 mg/kg and the maximum use levels are in the range of 0.4 - 100 mg/kg (EFFA, 2002i; 
EFFA, 2004ae; Flavour Industry, 2007m; EFFA, 2007a).  
The mTAMDI values for the candidate substances from structural class I are 72 and 2300 
microgram/person/day for 4-prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-
methylbutyrate, respectively. 
For detailed information on use levels and intake estimations based on the mTAMDI approach, see 
Section 6 and Annex II. 
 
                                                     
 
5 ”Normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th percentile of reported 
usages (EFFA, 2002i). 
6 The normal and maximum use levels in different food categories (EC, 2000) have been extrapolated from figures derived 
from 12 model flavouring substances (EFFA, 2004e). 
7 The use levels from food category 5 “Confectionery” have been inserted as default values for food category 14.2 
“Alcoholic beverages” for substances for which no data have been given for food category 14.2 (EFFA, 2007a). 
Flavouring Group Evaluation 30, Revision 1 
 
 
9 EFSA Journal 2011; 9(5):1991 
Table 3.1 Use of Candidate Substances 
Food 
category 
Description Flavourings used 
01.0 Dairy products, excluding products of category 2 [FL-no: 04.097, 
09.894] 
02.0 Fats and oils, and fat emulsions (type water-in-oil) [FL-no: 09.894] 
03.0 Edible ices, including sherbet and sorbet [FL-no: 04.097, 
09.894] 
04.1 Processed fruits [FL-no: 09.894] 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and 
legumes), and nuts & seeds 
None 
05.0 Confectionery [FL-no: 04.097, 
09.894] 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
[FL-no: 09.894] 
07.0 Bakery wares [FL-no: 04.097, 
09.894] 
08.0 Meat and meat products, including poultry and game [FL-no: 09.894] 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  [FL-no: 09.894] 
10.0 Eggs and egg products None 
11.0 Sweeteners, including honey None 
12.0 Salts, spices, soups, sauces, salads, protein products etc. [FL-no: 09.894] 
13.0 Foodstuffs intended for particular nutritional uses [FL-no: 09.894] 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products [FL-no: 04.097] 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts [FL-no: 04.097, 
09.894] 
15.0 Ready-to-eat savouries [FL-no: 09.894] 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be 
placed in categories 1 – 15 
[FL-no: 09.894] 
 
4. Absorption, Distribution, Metabolism and Elimination 
The candidate substances in this FGE are 4-prop-1-enylphenol and the 3-methylbutyrate ester of the 
structurally related isoeugenol. 
Esters of isoeugenol are anticipated to be hydrolysed in vivo by carboxylesterases (Heymann, 1980). 
Isoeugenol is rapidly absorbed from the gastrointestinal tract and metabolised principally in the liver 
via conjugation of the phenolic hydroxy group with sulphate or glucuronic acid. The conjugate is 
subsequently excreted, primarily in the urine (Badger et al., 2002b; Fuciarelli, 2001). The same 
metabolic pathway is anticipated for the 4-prop-1-enylphenol. The carboxylic acid resulting from the 
ester hydrolysis of [FL-no: 09.894] is metabolised in well-recognised biochemical pathways 
(Williams, 1959a). 
The Panel concluded that the candidate substances could be anticipated to be metabolised to innocuous 
products. 
For more detailed information, see Annex III. 
5. Application of the Procedure for the Safety Evaluation of Flavouring Substances 
The application of the Procedure is based on intakes estimated on the basis of the MSDI approach. 
Where the mTAMDI approach indicates that the intake of a flavouring substance might exceed its 
corresponding threshold of concern, a formal safety assessment is not carried out using the Procedure. 
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In these cases the Panel requires more precise data on use and use levels. For comparison of the intake 
estimations based on the MSDI approach and the mTAMDI approach, see Section 6. 
For the safety evaluation of the candidate substances from chemical group 17 the Procedure as 
outlined in Annex I was applied, based on the MSDI approach. The stepwise evaluation of the 
substances is summarised in Table 2a. 
Step 1 
The candidate substances are classified according to the decision tree approach by Cramer et al. 
(Cramer et al., 1978) into structural class I. 
Step 2 
At the estimated level of intakes, 4-prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-
methylbutyrate are expected to be metabolised to innocuous products. Accordingly, the evaluation of 
the substances proceeds via the A-side of the Procedure scheme (Annex I). 
Step A3 
The estimated level of the European daily per capita intake (MSDI) for the candidate substances 
classified into structural class I is 0.012 and 12 microgram (Table 2a), which is below the threshold of 
concern of 1800 microgram/person/day for structural class I substances. 
Accordingly, 4-prop-1-enylphenol [FL-no: 04.097] and 2-methoxy-4-(prop-1-enyl)phenyl 3-
methylbutyrate [FL-no: 09.894] are not expected to be of safety concern when used as flavouring 
substances at their estimated levels of intake, based on the MSDI approach. 
6. Comparison of the Intake Estimations Based on the MSDI Approach and the mTAMDI 
Approach 
The estimated intakes of [FL-no: 04.097 and 09.894] from structural class I based on the mTAMDI are 
72 and 2300 microgram/person/day, respectively. For [FL-no: 09.894] the mTAMDI  is above the 
threshold of concern of 1800 microgram/person/day for structural class I. Therefore, for  [FL-no: 
09.894] further information is required. This would include more reliable intake data and then, if 
required, additional toxicological data. 
For comparison of the intake estimates based on the MSDI approach and the mTAMDI approach, see 
Table 6.1. 
 
Table 6.1 Estimated intakes based on the MSDI approach and the mTAMDI approach 
FL-no EU Register name MSDI 
(μg/capita/day) 
mTAMDI 
(μg/person/day) Structural class 
Threshold of 
concern 
(µg/person/day) 
04.097 4-Prop-1-enylphenol 12 72 Class I 1800 
09.894 2-Methoxy-4-(prop-1-enyl)phenyl 3-
methylbutyrate 0.012 2300 Class I 1800 
7. Considerations of Combined Intakes from Use as Flavouring Substances 
Because of structural similarities of candidate and supporting substances, it can be anticipated that 
many of the flavourings are metabolised through the same metabolic pathways and that the 
metabolites may affect the same target organs. Further, in case of combined exposure to structurally 
related flavourings, the pathways could be overloaded. Therefore, combined intake should be 
considered. As flavourings not included in this FGE may also be metabolised through the same 
Flavouring Group Evaluation 30, Revision 1 
 
 
11 EFSA Journal 2011; 9(5):1991 
pathways, the combined intake estimates presented here are only preliminary. Currently, the combined 
intake estimates are only based on MSDI exposure estimates, although it is recognised that this may 
lead to underestimation of exposure. After completion of all FGEs, this issue should be readdressed. 
The total estimated combined daily per capita intake of structurally related flavourings is estimated by 
summing the MSDI for individual substances. 
The combined intake of the two candidate substances from their use as flavouring substances is 12 
micogram/capita/day which is below the threshold of concern for of 1800 microgram/person/day for a 
structural class I substance.  
The candidate substances are structurally related to six supporting substances evaluated by the JEFCA 
at its 61st meeting (JECFA, 2004a). The combined intake of the six supporting substances from 
structural class I could be estimated to approximately 140 microgram/capita/day.  
The total combined intake from candidate and supporting substances in Europe is approximately 150 
microgram/capita/day, which is below the threshold of concern of a structural class I substance of 
1800 microgram/person/day. 
8. Toxicity 
8.1. Acute Toxicity 
No information on acute toxicity is available for the candidate substances. Oral LD50 values have been 
reported for four of the six supporting substances in this group and ranged from 290 to 3500 mg/kg 
body weight (bw) in rats and Guinea pigs. 
The acute toxicity data are summarised in Annex IV, Table IV.1. 
8.2. Subacute, Subchronic, Chronic and Carcinogenicity Studies 
No information is available for the candidate substances. Subchronic and chronic studies have been 
performed in rats and mice for the supporting substance isoeugenol [FL-no: 04.004] and a 29-day 
study has been performed in rats for the supporting substance 6-ethoxyprop-3-enylphenol [FL-no: 
04.002].  
Isoeugenol [FL-no: 04.004] 
Rats 
A subchronic oral toxicity study (NTP, 2002b) was performed in male and female rats which were 
administered by gavage doses of 0, 37.5, 75, 150, 300 or 600 mg isoeugenol/kg bw, 5 times per week, 
for 14 weeks. A treatment related effect on body weight was observed for the high dose male group 
only. The liver weights in female rats receiving the two highest doses, 300 and 600 mg/kg bw, were 
significantly increased: minimal to mild periportal hepatocellular cytoplasmic alteration occurred in all 
300 and 600 mg/kg bw females. In addition, atrophy of the olfactory epithelium of the nose and 
olfactory nerve bundles was observed in both sexes (NTP, 2002b). 
In a subsequent chronic study (NTP, 2010a) groups of 50 male and 50 female F344/N rats were 
administered isoeugenol in corn oil by gavage at doses of 0, 75, 150 or 300 mg/kg bw, 5 days per 
week, except holidays, for 105 weeks. Survival rates of the exposed male and female rats were similar 
to those of the vehicle controls. Mean body weights of the highest dose group male rats were 9 % 
greater than the vehicle controls at the end of the study (NTP, 2010a).  
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Two male rats in the 300 mg/kg bw/day group had rare benign or malignant thymomas, while two 
other males in this group had rare mammary gland carcinomas. The incidences of minimal atrophy and 
minimal to mild respiratory metaplasia of the olfactory epithelium were increased in 150 mg/kg 
bw/day males and 300 mg/kg bw/day males and females. The incidence of minimal to mild olfactory 
epithelial degeneration in 300 mg/kg bw/day males was also increased. The incidences of 
keratoacanthoma of the skin were decreased in 150 and 300 mg/kg bw/day males.  
In the technical report of the NTP study (NTP, 2010a) it was concluded that “there was equivocal 
evidence of carcinogenic activity of isoeugenol in male F344/N rats based on increased incidences of 
rarely occurring thymoma and mammary gland carcinoma. There was no evidence of carcinogenic 
activity of isoeugenol in female F344/N rats”.  
Mice 
In a 3-month repeated dose toxicity study (NTP, 2002b) B6C3F1 mice were given isoeugenol orally by 
gavage at doses of 0, 37.5, 75, 150, 300 or 600 mg/kg bw, 5 days per week, for up to 14 weeks. The 
liver weights in the 300 and 600 mg/kg males were significantly increased. In addition, atrophy of the 
olfactory epithelium and nerve bundles was observed in both sexes at the 600 mg/kg dose.  
The above dose-range finding study was followed by a 2 year carcinogenicity study in the same strain 
of mice. Male and female mice (n = 50 per experimental group) were exposed to isoeugenol in corn oil 
by gavage at doses of 0, 75, 150 or 300 mg/kg bw, 5 days per week, except holidays, for 104 (females) 
or 105 (males) weeks. Survival of 300 mg/kg bw/day males was significantly decreased compared to 
the vehicle controls. Mean body weights of 300 mg/kg bw/day male and female groups were less than 
those of vehicle controls after weeks 75 (8 %) and 64 (15 %), respectively (NTP, 2010a).  
In all groups of exposed males, the incidences of hepatocellular adenoma, hepatocellular carcinoma, 
and hepatocellular adenoma or carcinoma (combined) were significantly greater than those in the 
vehicle control group; incidences of multiple hepatocellular adenoma were also significantly 
increased. Incidences of clear cell focus were significantly increased in 75 and 150 mg/kg bw/day 
male mice. There was a significant positive trend in the incidences of histocytic sarcoma in females, 
and this neoplasm occurred in multiple tissues. Incidences of respiratory metaplasia in the olfactory 
epithelium in all exposed groups, and of atrophy and hyaline droplet accumulation in all exposed 
groups except 75 mg/kg bw/day females, were significantly greater than those in the corresponding 
vehicle control groups. Incidences of minimal to marked hyperplasia of Bowman’s gland were 
increased significantly in all exposed groups. The incidences of minimal to moderate necrosis of renal 
papilla and tubules were increased significantly in 300 mg/kg bw/day females. Incidences of 
forestomach squamous hyperplasia, inflammation and ulceration (males only) increased with 
increasing exposure concentration and were significant in the 300 mg/kg bw/day groups. The 
incidence of glandular stomach ulcers was significantly increased in the 300 mg/kg bw/day groups.  
Exposure to isoeugenol resulted in non-neoplastic lesions of the nose in male and female rats and the 
nose, forestomach, and glandular stomach in male and female mice. 
In the technical report of the NTP study (NTP, 2010a) it was concluded that “there was clear evidence 
of carcinogenic activity of isoeugenol in male B6C3F1 mice based on increased incidences of 
hepatocellular adenoma, hepatocellular carcinoma and hepatocellular adenoma or carcinoma 
(combined). There was equivocal evidence of carcinogenic activity of isoeugenol in female B6C3F1 
mice based on increased incidences of histiolytic sarcoma”.  
The Panel noted that liver changes (slight increased liver-to-body weight ratio) were also detectable at 
all dose levels in male mice from the 90-day oral study and considered this effect to be consistent with 
the non genotoxic-mediated (see Section 8.4) liver carcinogenesis seen in the 2-year study in the same 
mouse strain. The Panel also noted that: 
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i. isoeugenol did not increase the incidence of liver cancer in other species (Fischer 344 rats), or 
gender (female mice) 
ii. no dose-response was identified in hepatic tumour incidence in mice 
iii. the B6C3F1 mouse strain is known to be very sensitive to increases in liver tumours by non-
genotoxic mechanisms (e.g. Phenobarbital) 
iv. isoeugenol is not genotoxic (see Section 8.4). 
On these grounds, the Panel considered that these experimental findings were unlikely to be relevant 
to humans.  
In conclusion, the Panel considered that elicitation of tumours in rodents is connected to a non 
genotoxic mechanism. Therefore, the candidate substance can be evaluated via a threshold based 
approach. 
Repeated dose toxicity data are summarised in Annex IV, Table IV.2. 
8.3. Developmental / Reproductive Toxicity Studies 
Information on developmental or reproductive toxicity is only available for the supporting substance 
isoeugenol. 
A multigenerational reproductive toxicity study was performed in male and female Sprague-Dawley 
rats which were dosed with 0, 70, 230 or 700 mg of isoeugenol per kg bw per day by gavage in corn 
oil (EMEA, 2009). Rats from the F0 generation were mated and produced three litters (F1a, F1b and 
F1c). Animals from the F1c litters were first exposed to isoeugenol on postnatal day 21. On postnatal 
days 71 to 91, F1c animals were assigned to mating pairs and produced three litters (F2a, F2b, and 
F2c). The highest dose of isoeugenol, i.e. 700 mg/kg per day, caused mild reproductive toxicity 
(decreased number of F1 pups per litter and reduced F2 male and female pup weights). 
A developmental toxicity study (NTP, 1998; George et al., 2001) was carried out in timed-pregnant 
CD® outbred albino Sprague-Dawley rats which were treated with 250, 500 or 1,000 mg/kg of 
isoeugenol by gavage in corn oil from gestational day (GD) 6 to GD 19. No prenatal mortality was 
detected at any dose. Average fetal body weight per litter was decreased by 7 % (male) or 9 % 
(female) in the 1,000 mg/kg group on gestation day 20. No other statistically significant fetal 
abnormalities were observed, besides an increased incidence of unossified sternebra in fetuses from 
the 1,000 mg/kg group.  
Data on developmental and reproductive toxicity are summarised in Annex IV, Table IV.3. 
8.4. Genotoxicity Studies 
No data on genotoxicity are available for the candidate substances. However, there are data for three 
supporting substances from in vitro tests and for three supporting substances from in vivo assays. 
The most relevant supporting substance is isoeugenol because it may result from hydrolysis of the 
candidate substance.  
Negative results were obtained for isoeugenol in a battery of four standard tests (three in vitro and one 
in vivo), covering important genetic endpoints such as gene mutations, chromosome aberrations and 
unscheduled DNA synthesis (UDS). In particular, isoeugenol was unable to induce gene mutations in 
bacterial cells (S. typhimurium and E. coli), chromosome aberrations in Chinese hamster ovary (CHO) 
cells and UDS in cultured hepatocytes from male F344 rats and female B6C3F1 mice. There are 
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conflicting results, one positive and one negative findings in two bacterial DNA repair (Rec assay) 
assays in B. subtilis, but as this bacterial DNA-repair test system is of low predictive value for 
genotoxicity it will not change the overall evaluation. The conflicting results of two in vitro sister 
chromatid exchanges (SCE) (one negative in CHO cells up to non cytotoxic concentrations, and one 
positive in human lymphocytes at higher concentrations eliciting cytotoxicity) are considered of 
limited relevance for the overall evaluation, taking into account the results of the other standard tests. 
This endpoint is known to be induced also by non-genotoxic agents (e.g.: inhibitors of DNA synthesis, 
tumour promoters etc.) and is generally considered less relevant than mutations at the gene or 
chromosome level.  
In vivo, isoeugenol was negative in the Wing Spot somatic mutation/recombination test in Drosophila, 
as well as, most important, in a mouse bone marrow micronucleus assay carried out by oral gavage in 
male animals up to 2000 mg/kg bw, with evidence of bone marrow exposure, shown by a decreased 
incidence of polychromatic erythrocytes (PCEs) in the treated groups (EMEA, 2009).  
Recently the NTP studied the genotoxicity of isoeugenol in association with a carcinogenicity study in 
rats and mice (NTP, 2010a) see Section 8.2.). All tests were negative except those of 90-day in vivo 
micronucleus results in which a three-fold increase in the frequencies of micronucleated 
normochromatic erythrocytes were observed in female mice at the highest dose (600 mg/kg bw/day). 
However, the Panel noted that this weak effect was only observed in the female mice and did not 
correlate with an observed carcinogenic activity. Only clearcut positive results of this type of test can 
be taken into account for an overall evaluation of the genotoxic potential, but this is not the case of 
isoeugenol. Several weaknesses were also identified in the micronucleus study design and results, such 
as the lack of inclusion of a positive control, the lack of historical control data and the lack of 
consistency in the control data sets between sexes. 
The Panel was informed that two new studies had been submitted to EMEA in connection with the use 
of eugenol as stunning agent for fish.  
These two genotoxicity studies were an in vivo micronucleus test in male and female CD-1 mice and 
an in vivo DNA repair (UDS) test in male and female Sprague-Dawley rats. Both studies were 
negative (EMEA, 2009). 
The new in vivo micronucleus test in mice did not demonstrate any genotoxic effect of isoeugenol at 
oral gavage doses up to 2000 mg/kg/day and 1500 mg/kg/day in males and females, respectively. 
Negative results were also obtained in the in vivo UDS test in rats which were orally (by gavage) 
exposed to doses as high as 2000 mg/kg (males) and 1250 mg/kg (females) (EMEA, 2009).  
Based on the weight of in vitro and in vivo evidence, the Panel concluded that isoeugenol is not 
genotoxic.  
In vitro, the supporting substance 6-ethoxyprop-3-enylphenol [FL-no: 04.002] was negative in two 
Ames tests and in the rat hepatocytes UDS assay (see Table IV.4); it was positive in the mouse 
lymphoma assay in the presence of S9. In vivo, it was unable to induce gene mutations in the Sex 
Linked Recessive Lethal assay in Drosophila as well as micronuclei in mice treated intraperitoneally 
up to 1947 mg/kg bw. Notwithstanding the fact that the studies were carried out in 1982 and 1983 not 
fully in compliance with current OECD guidelines, the results can be considered sufficiently adequate 
for an evaluation. Overall, the data available do not raise concern for genotoxity.  
In conclusion, the Panel considered that isoeugenol was not genotoxic and that the available data on 
the supporting substances as well as the structure of the candidate substance do not give rise to safety 
concern with respect to genotoxicity.  
According to the NTP (NTP, 2010a) report there were clear evidence of carcinogenic activity of 
isoeugenol in male B6C3F1 mice (hepatocellular adenoma and/or carcinoma) and equivocal evidence 
of carcinogenic activity of isoeugenol in female B6C3F1 mice (histiocytic sarcoma) and male F344/N 
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rats (rare thymoma and mammary gland carcinoma). The Panel however concluded that these 
observations would not prevent the candidate substance from being evaluated through the Procedure, 
given the lack of genotoxic potential of isoeugenol.  
Genotoxicity data are summarised in Annex IV, Table IV.4 and Table IV.5. 
9. Conclusions 
The candidate substances are 4-prop-1-enylphenol [FL-no: 04.097] and a structurally related ester,  2-
methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate [FL-no: 09.894], both from chemical group 17. 
Due to the presence and the position of a double bond both candidate substances can exist as 
geometrical isomers. For 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate the stereoisomeric 
composition has been specified as the E/Z mixture, but the composition of the mixture has not been 
given.  
4-Prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate are classified into 
structural class I.  
The candidate substances have been reported to occur naturally in anise oil and cider. 
According to the default MSDI approach, the flavouring substances in this group have European 
intakes of 0.012 and 12 microgram/capita/day ([FL-no: 09.894 and 04.097], respectively), which are 
below the threshold of concern for structural class I substances of 1800 microgram/person/day. 
On the basis of the reported annual production in Europe (MSDI approach) the total combined intake 
of the two flavouring substances and six structurally related substances from structural class I can be 
calculated to approximately 150 microgram/capita/day. This value is lower than the threshold of 
concern for structural class I substances of 1800 microgram/person/day. 
Data available do not give rise to safety concern with respect to genotoxicity. 
4-Prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate are expected to be 
metabolised to innocuous products. 
It was noted that where toxicity data were available they were consistent with the conclusions in the 
present Flavouring Group Evaluation. The Panel considered that elicitation of tumours by the 
supporting substance isoeugenol in rodents is connected to a non genotoxic mechanism. Therefore, the 
flavouring substances [FL-no: 04.097 and 09.894] can be evaluated via a threshold based approach, 
i.e. the Procedure. 
It is considered that on the basis of the default MSDI approach the candidate substances would not 
give rise to safety concern at the estimated levels of intake arising from use as flavouring substances. 
When the estimated intake was based on the mTAMDI approach it was 72 and 2300 
microgram/person/day for 4-prop-1-enylphenol and 2-methoxy-4-(prop-1-enyl)phenyl 3-
methylbutyrate, respectively. For 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate this intake 
estimate is above the threshold of concern for structural class I substances of 1800 
microgram/person/day, and therefore,  more reliable exposure data are required for this substance. On 
the basis of such additional data, the flavouring substance should be reconsidered along the steps of 
the Procedure. Following this Procedure additional toxicological data might become necessary. 4-
Prop-1-enylphenol, for which the estimated intake is below the threshold, is also expected to be 
metabolised to innocuous products.  
In order to determine whether the conclusion for the two flavouring substances can be applied to the 
materials of commerce, it is necessary to consider the available specifications. Adequate 
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specifications, including complete purity criteria and identity, have been given for 4-prop-1-
enylphenol [FL-no: 04.097] and 2-methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate [FL-no: 09.894], 
except that information on  the composition of the stereoisomeric mixture has not been specified for 
[FL-no: 09.894]. Thus, the final evaluation of the material of commerce cannot be performed for 2-
methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate [FL-no: 09.894] pending further information on 
specifications. 
For  4-prop-1-enylphenol [FL-no: 04.097] the Panel concluded that it would present no safety concern 
at the estimated level of intake based on the MSDI approach. 
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TABLE 1: SPECIFICATION SUMMARY OF THE SUBSTANCES IN THE FLAVOURING GROUP EVALUATION 30REV1 
Table 1: Specification Summary of the Substances in the Flavouring Group Evaluation  30Rev1 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 1) 
Solubility in ethanol 
2) 
Boiling point, °C 3) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 4) 
Spec.gravity 5) 
Specification comments 
04.097 
 
4-Prop-1-enylphenol OH 4062 
 
539-12-8 
Solid 
C9H10O 
134.18 
Slightly soluble 
Soluble 
250 
94 
MS 
97.7%  
n.a. 
n.a. 
Minimum assay value: 
97.7 % ( 95.2 % trans and 
2.5 % cis). 
09.894 
 
2-Methoxy-4-(prop-1-enyl)phenyl 
3-methylbutyrate 
O
O
O
 
 
 
 
Solid 
C15H20O3 
248.32 
Practically insoluble or 
insoluble 
Freely soluble 
223 
81 
NMR 
95 % 
n.a. 
n.a. 
CASrn 61114-23-6 to be 
introduced in the Register 
(EFFA, 2004ae). The 
CASrn does not specify 
isomer. 
Mixture of E & Z isomers 
(EFFA, 2010a). 
Composition of mixture to 
be specified. 
1) Solubility in water, if not otherwise stated. 
2) Solubility in 95 %  ethanol, if not otherwise stated. 
3) At 1013.25 hPa, if not otherwise stated. 
4) At 20°C, if not otherwise stated. 
5) At 25°C, if not otherwise stated. 
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TABLE 2A: SUMMARY OF SAFETY EVALUATION APPLYING THE PROCEDURE (BASED ON INTAKES CALCULATED BY THE MSDI APPROACH) 
Table 2a: Summary of Safety Evaluation Applying the Procedure (based on intakes calculated by the MSDI approach) 
FL-no EU Register name Structural formula MSDI 1) 
(μg/capita/day) 
Class 2) 
Evaluation procedure path 3) 
Outcome on the 
named compound 
[ 4) or 5)] 
Outcome on the 
material of 
commerce [6), 7), 
or 8)] 
Evaluation 
remarks 
04.097 
 
4-Prop-1-enylphenol OH 12 
 
Class I 
A3: Intake below threshold 
4) 6)  
09.894 
 
2-Methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate O
O
O
0.012 
 
Class I 
A3: Intake below threshold 
4) 7)  
1) EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
3) Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
4) No safety concern based on intake calculated by the MSDI approach of the named compound. 
5) Data must be available on the substance or closely related substances to perform a safety evaluation. 
6) No safety concern at estimated level of intake of the material of commerce meeting the specification of Table 1 (based on intake calculated by the MSDI approach). 
7) Tentatively regarded as presenting no safety concern (based on intake calculated by the MSDI approach) pending further information on the purity of the material of commerce and/or information on stereoisomerism. 
8) No conclusion can be drawn due to lack of information on the purity of the material of commerce. 
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TABLE 2B: EVALUATION STATUS OF HYDROLYSIS PRODUCTS OF CANDIDATE ESTERS  
Table 2b: Evaluation Status of Hydrolysis Products of Candidate Esters 
FL-no EU Register name 
JECFA no 
Structural formula SCF status 1) 
JECFA status 2) 
CoE status 3) 
EFSA status 
Structural class 4) 
Procedure path (JECFA) 5) 
Comments 
04.004 Isoeugenol 
1260 
OH
O
 
No safety concern a) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
08.008 3-Methylbutyric acid 
259 
OH
O
 
Category 1 c) 
No safety concern d) 
Category A b) 
 
Class I 
A3: Intake below threshold 
 
1) Category 1: Considered safe in use   Category 2: Temporarily considered safe in use   Category 3: Insufficient data to provide assurance of safety in use   Category 4): Not acceptable due to evidence of toxicity. 
2) No safety concern at estimated levels of intake. 
3) Category A: Flavouring substance, which may be used in foodstuffs Category B: Flavouring substance which can be used provisionally in foodstuffs. 
4) Threshold of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
5) Procedure path A substances can be predicted to be metabolised to innocuous products. Procedure path B substances cannot. 
a) (JECFA, 2004a). 
b) (CoE, 1992). 
c) (SCF, 1995). 
d) (JECFA, 1999b). 
ND: Not detected. 
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TABLE 3: SUPPORTING SUBSTANCES SUMMARY 
Table 3: Supporting Substances Summary 
FL-no EU Register name Structural formula FEMA no 
CoE no 
CAS no 
JECFA no  
Specification available 
MSDI (EU) 1) 
(μg/capita/day) 
SCF status 2) 
JECFA status 3) 
CoE status 4) 
EFSA Comments 
04.002 6-Ethoxyprop-3-enylphenol O
OH  
2922 
170 
94-86-0 
1264 
JECFA specification 
(JECFA, 2003b) 
38 - 
No safety concern a) 
Category A b) 
Registername to be changed to 
6-Ethoxy-3-(prop-3-
enyl)phenol. 
Composition of stereoisomeric 
mixture to be specified. 
04.004 Isoeugenol OH
O
2468 
172 
97-54-1 
1260 
JECFA specification 
(JECFA, 2003b) 
99 - 
No safety concern a) 
Category A b) 
Composition of stereoisomeric 
mixture to be specified. 
04.055 2,6-Dimethoxy-4-prop-1-enylphenol O
O
OH
3728 
- 
20675-95-0 
1265 
JECFA specification 
(JECFA, 2003b) 
0.012 - 
No safety concern a) 
- 
Register name to be changed to 
E-2,6-Dimethoxy-4-prop-1-
enylphenol. 
Composition of stereoisomeric 
mixture to be specified. 
09.030 2-Methoxy-4-(prop-1-enyl)phenyl 
acetate 
O
O
O
2470 
220 
93-29-8 
1262 
JECFA specification 
(JECFA, 2003b) 
0.61 - 
No safety concern a) 
Category B b) 
Composition of stereoisomeric 
mixture to be specified. 
09.089 Isoeugenyl formate O
O
O
2474 
356 
7774-96-1 
1261 
JECFA specification 
(JECFA, 2003b) 
0.012 - 
No safety concern a) 
Category B b) 
Composition of stereoisomeric 
mixture to be specified. 
09.710 Isoeugenyl phenylacetate O
O
O
2477 
237 
120-24-1 
1263 
JECFA specification 
(JECFA, 2005b) 
0.085 - 
No safety concern a) 
Category B b) 
Composition of stereoisomeric 
mixture to be specified. 
1) EU MSDI: Amount added to food as flavouring substance in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
2) Category 1: Considered safe in use, Category 2: Temporarily considered safe in use, Category 3: Insufficient data to provide assurance of safety in use, Category 4: Not acceptable due to evidence of toxicity. 
3) No safety concern at estimated levels of intake. 
4) Category A: Flavouring substance, which may be used in foodstuffs, Category B: Flavouring substance which can be used provisionally in foodstuffs. 
a) (JECFA, 2004a). 
b) (CoE, 1992). 
ND)  No intake data reported. 
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ANNEX I: PROCEDURE FOR THE SAFETY EVALUATION 
The approach for a safety evaluation of chemically defined flavouring substances as referred to in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a), named the "Procedure", is shown in schematic 
form in Figure I.1. The Procedure is based on the Opinion of the Scientific Committee on Food expressed on 
2 December 1999 (SCF, 1999a), which is derived from the evaluation Procedure developed by the Joint 
FAO/WHO Expert Committee on Food Additives at its 44th, 46th and 49th meetings (JECFA, 1995; JECFA, 
1996a; JECFA, 1997a; JECFA, 1999b). 
The Procedure is a stepwise approach that integrates information on intake from current uses, structure-
activity relationships, metabolism and, when needed, toxicity. One of the key elements in the Procedure is 
the subdivision of flavourings into three structural classes (I, II, III) for which thresholds of concern (human 
exposure thresholds) have been specified. Exposures below these thresholds are not considered to present a 
safety concern. 
Class I contains flavourings that have simple chemical structures and efficient modes of metabolism, which 
would suggest a low order of oral toxicity. Class II contains flavourings that have structural features that are 
less innocuous, but are not suggestive of toxicity. Class III comprises flavourings that have structural 
features that permit no strong initial presumption of safety, or may even suggest significant toxicity (Cramer 
et al., 1978). The thresholds of concern for these structural classes of 1800, 540 or 90 microgram/person/day, 
respectively, are derived from a large database containing data on subchronic and chronic animal studies 
(JECFA, 1996a). 
In Step 1 of the Procedure, the flavourings are assigned to one of the structural classes. The further steps 
address the following questions: 
• can the flavourings be predicted to be metabolised to innocuous products8 (Step 2)?  
• do their exposures exceed the threshold of concern for the structural class (Step A3 and B3)? 
• are the flavourings or their metabolites endogenous9 (Step A4)?  
• does a NOAEL exist on the flavourings or on structurally related substances (Step A5 and B4)? 
In addition to the data provided for the flavouring substances to be evaluated (candidate substances), 
toxicological background information available for compounds structurally related to the candidate 
substances is considered (supporting substances), in order to assure that these data are consistent with the 
results obtained after application of the Procedure.  
The Procedure is not to be applied to flavourings with existing unresolved problems of toxicity. Therefore, 
the right is reserved to use alternative approaches if data on specific flavourings warranted such actions. 
 
                                                     
 
8 “Innocuous metabolic products”: Products that are known or readily predicted to be harmless to humans at the 
estimated intakes of the flavouring agent” (JECFA, 1997a). 
 
9 “Endogenous substances”: Intermediary metabolites normally present in human tissues and fluids, whether free or 
conjugated; hormones and other substances with biochemical or physiological regulatory functions are not included 
(JECFA, 1997a). 
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Decision tree structural class 
Can the substance be predicted to be metabolised to innocuous products?
Procedure for Safety Evaluation of Chemically Defined Flavouring Substances 
Do the conditions of use result in an intake greater than the 
threshold of concern for the structural class?
Do the conditions of use result in an intake greater than the  
threshold of concern for the structural class? 
Data must be available on the  
substance or closely related  
substances to perform a safety 
evaluation
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
Does a NOAEL exist for the substance which provides an adequate 
margin of safety under conditions of intended use, or does a NOAEL 
exist for structurally related substances which is  high enough to 
accommodate any perceived difference in toxicity between the 
substance and the related substances? 
  Substance would not be    
expected to be of safety concern
Is the substance or are its metabolites endogenous?
Additional data required 
Step 1. 
Step 2. 
Step A3. 
Step A4. 
Step A5. 
Step B3. 
Step B4.
 Yes No
 Yes 
 No 
No
No
Yes
No
Yes
Yes
Yes
 No
Figure I.1 Procedure for Safety Evaluation of Chemically Defined Flavouring Substances
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ANNEX II: USE LEVELS / MTAMDI 
II.1 Normal and Maximum Use Levels 
For each of the 18 Food categories (Table II.1.1) in which the candidate substances are used, Flavour 
Industry reports a “normal use level” and a “maximum use level” (EC, 2000a). According to the Industry the 
”normal use” is defined as the average of reported usages and ”maximum use” is defined as the 95th 
percentile of reported usages (EFFA, 2002i). The normal and maximum use levels in different food 
categories have been extrapolated from figures derived from 12 model flavouring substances (EFFA, 2004e). 
Table II.1.1 Food categories according to Commission Regulation (EC) No 1565/2000 (EC, 2000a) 
Food category Description 
01.0 Dairy products, excluding products of category 02.0 
02.0 Fats and oils, and fat emulsions (type water-in-oil) 
03.0 Edible ices, including sherbet and sorbet 
04.1 Processed fruit 
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), and nuts & seeds 
05.0 Confectionery 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & legumes, excluding bakery 
07.0 Bakery wares 
08.0 Meat and meat products, including poultry and game 
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  
10.0 Eggs and egg products 
11.0 Sweeteners, including honey 
12.0 Salts, spices, soups, sauces, salads, protein products, etc. 
13.0 Foodstuffs intended for particular nutritional uses 
14.1 Non-alcoholic ("soft") beverages, excl. dairy products 
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts 
15.0 Ready-to-eat savouries 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be placed in categories 01.0 - 15.0 
 
The “normal and maximum use levels” are provided by Industry for the candidate substances in the present 
flavouring group (Table II.1.2). 
Table II.1.2 Normal and Maximum use levels (mg/kg) for the candidate substances in FGE.30Rev1 (EFFA, 
2004ae; EFFA, 2007a; Flavour Industry, 2007m). 
FL-no Food Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.
0 
04.097 0,15 
0,6 
- 
- 
0,15 
0,7 
- 
- 
- 
- 
0,35 
1,7 
- 
- 
0,2 
1 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
- 
0,1 
0,4 
0,15 
0,7 
- 
- 
- 
- 
09.894 7 
35 
5 
25 
10 
50 
7 
35 
- 
- 
10 
50 
5 
25 
10 
50 
2 
10 
2 
10 
- 
- 
- 
- 
5 
25 
10 
50 
- 
- 
10 
50 
20 
100 
5 
25 
II.2 mTAMDI Calculations 
The method for calculation of modified Theoretical Added Maximum Daily Intake (mTAMDI) values is 
based on the approach used by SCF up to 1995 (SCF, 1995). The assumption is that a person may consume 
the amount of flavourable foods and beverages listed in Table II.2.1. These consumption estimates are then 
multiplied by the reported use levels in the different food categories and summed up.  
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Table II.2.1 Estimated amount of flavourable foods, beverages, and exceptions assumed to be consumed per 
person per day (SCF, 1995) 
Class of product category Intake estimate (g/day) 
Beverages (non-alcoholic) 324.0 
Foods 133.4 
Exception a: Candy, confectionery 27.0 
Exception b: Condiments, seasonings 20.0 
Exception c: Alcoholic beverages 20.0 
Exception d: Soups, savouries 20.0 
Exception e: Others, e.g. chewing gum e.g. 2.0 (chewing gum) 
 
The mTAMDI calculations are based on the normal use levels reported by Industry. The seven food 
categories used in the SCF TAMDI approach (SCF, 1995) correspond to the 18 food categories as outlined in 
Commission Regulation (EC) No 1565/2000 (EC, 2000a) and reported by the Flavour Industry in the 
following way (see Table II.2.2): 
• Beverages (SCF, 1995) correspond to food category 14.1 (EC, 2000a) 
• Foods (SCF, 1995) correspond to the food categories 1, 2, 3, 4.1, 4.2, 6, 7, 8, 9, 10, 13, and/or 16 
(EC, 2000a) 
• Exception a (SCF, 1995) corresponds to food category 5 and 11 (EC, 2000a) 
• Exception b (SCF, 1995) corresponds to food category 15 (EC, 2000a) 
• Exception c (SCF, 1995) corresponds to food category 14.2 (EC, 2000a) 
• Exception d (SCF, 1995) corresponds to food category 12 (EC, 2000a) 
• Exception e (SCF, 1995) corresponds to others, e.g. chewing gum. 
Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
Key Food category Food Beverages Exceptions 
01.0 Dairy products, excluding products of category 02.0 Food   
02.0 Fats and oils, and fat emulsions (type water-in-oil) Food   
03.0 Edible ices, including sherbet and sorbet Food   
04.1 Processed fruit Food   
04.2 Processed vegetables (incl. mushrooms & fungi, roots & tubers, pulses and legumes), 
and nuts & seeds 
Food   
05.0 Confectionery   Exception a 
06.0 Cereals and cereal products, incl. flours & starches from roots & tubers, pulses & 
legumes, excluding bakery 
Food   
07.0 Bakery wares Food   
08.0 Meat and meat products, including poultry and game Food   
09.0 Fish and fish products, including molluscs, crustaceans and echinoderms  Food   
10.0 Eggs and egg products Food   
11.0 Sweeteners, including honey   Exception a 
12.0 Salts, spices, soups, sauces, salads, protein products, etc.    Exception d 
13.0 Foodstuffs intended for particular nutritional uses Food   
14.1 Non-alcoholic ("soft") beverages, excl. dairy products  Beverages  
14.2 Alcoholic beverages, incl. alcohol-free and low-alcoholic counterparts   Exception c 
15.0 Ready-to-eat savouries   Exception b 
16.0 Composite foods (e.g. casseroles, meat pies, mincemeat) - foods that could not be Food   
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Table II.2.2 Distribution of the 18 food categories listed in Commission Regulation (EC) No 1565/2000 (EC, 
2000a) into the seven SCF food categories used for TAMDI calculation (SCF, 1995) 
 Food categories according to Commission Regulation 1565/2000 Distribution of the seven SCF food categories 
placed in categories 01.0 - 15.0 
 
The mTAMDI values (see Table II.2.3) are presented for each of the flavouring substance in the present 
flavouring group, for which Industry has provided use and use levels (EFFA, 2004ae; EFFA, 2007a; Flavour 
Industry, 2007m). The mTAMDI values are only given for the highest reported normal use levels. 
TableII.2.3 Estimated intakes based on the mTAMDI approach 
FL-no EU Register name mTAMDI 
(μg/person/day) 
Structural class Threshold of concern 
(µg/person/day) 
04.097 4-Prop-1-enylphenol 72 Class I 1800 
09.894 2-Methoxy-4-(prop-1-enyl)phenyl 3-methylbutyrate 2300 Class I 1800 
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ANNEX III: METABOLISM 
Introduction 
The candidate substances in this FGE are hydroxypropenylbenzene derivatives, 4-prop-1-enylphenol and the 
3-methylbutyrate of the structurally related hydroxypropenylbenzene, isoeugenol. 
III.1. Hydrolysis 
In general, aromatic esters are hydrolysed in vivo through the catalytic activity of carboxylesterases 
(Heymann, 1980; Anders, 1989), the most important of which are the A-esterases. Carboxylesterases are 
found in the endoplasmic reticulum of most mammalian tissues; however, they are most abundant in 
hepatocytes (Anders, 1989; Graffner-Nordberg et al., 1998; Hosokawa et al., 2001).  
In a study of the hydrolysis of the structurally related ester, phenyl acetate, using pig liver carboxylesterase, 
the Km (substrate concentration at which half the true maximum velocity of an enzyme-catalysed reaction is 
achieved) and Vmax (maximum velocity of an enzyme-catalysed reaction) values for phenyl acetate were 
reported to be 0.43 mmol/l and 438 mmol/min per mg protein, respectively, at a substrate (phenyl acetate) 
concentration of 0.2–3 mmol/l (Junge & Heymann, 1979). A second phenolic ester, o-tolyl acetate (o-
methylphenyl acetate) was 60 % hydrolysed in vitro after incubation with pancreatin for 2 hours at 37°C 
(Grundschober, 1977). Phenyl 2-hydroxybenzoate (phenyl salicylate) is hydrolysed to phenol and 2-
hydroxybenzoic acid in humans, as shown in a study in which one man was given one capsule containing 90 
mg of phenyl salicylate per hour for 8 hours. Urine was collected for 72 hours after the first dose, in 8 hours 
collection periods. Analysis of total urinary phenol showed a peak concentration of 472 mg/l during the 
second collection period. The concentration of free urinary phenol peaked at 25 mg/l during the same period. 
Approximately 60 hours after the first dose, concentrations of both total and free urinary phenol returned to 
baseline levels (7 and 1 mg/l, respectively) (Fishbeck et al., 1975).  
Recent studies have revealed that isoeugenyl acetate [FL-no: 09.030] undergoes extensive hydrolysis when 
incubated with rat hepatocytes or with microsomes prepared from rat liver. For example, incubation of 
isoeugenyl acetate (500 µmol/l) with hepatocytes (2 million cells) resulted in the complete hydrolysis of the 
ester to isoeugenol within 15–20 min. Hydrolytic activity was greatly enriched in the endoplasmic reticulum 
(i.e. microsomal fraction) of the liver. Rat blood also hydrolysed isoeugenyl acetate at a rate of 1600 
nmol/ml per min (personal communication from Professor G. Sipes, University of Arizona, Tucson, Arizona, 
USA to the Flavor and Extract Manufacturers Association (FEMA), Washington, DC, USA; submitted to 
WHO by FEMA). 
III.2. Absorption, Distribution and Elimination 
In humans, rats and mice, orally administered hydroxypropenylbenzene derivatives are rapidly absorbed 
from the gastrointestinal tract and predominantly metabolized in the liver via phase II conjugation of the 
phenolic hydroxy (OH) group to form sulphate and glucuronic acid conjugates. These conjugates are 
eliminated primarily in the urine.  
Male Fischer 344 rats given [14C] isoeugenol at a single oral dose of 156 mg/kg bw excreted > 85 % of the 
administered dose as the glucuronic acid and sulphate conjugate in the urine within 72 hours. No parent 
compound was detected in the blood after oral administration at any time point. Similarly, male rats given 
[14C] isoeugenol at a single intravenous dose of 15.6 mg/kg bw excreted 82 % of the administered dose as 
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the glucuronic acid and sulphate conjugates in the urine within 72 hours. Isoeugenol disappeared rapidly 
from the rat blood. About 12 % of the administered dose was present in the blood at the first time point, i.e. 
0.017 hours, after intravenous administration, the calculated half-life (t1/2) was 12 min, and the systemic 
clearance was 1.9 l/min/kg. After administration by either route, approximately 10 % of the administered 
dose was excreted in the faeces and < 0.1 % was recovered in expired air. Less than 0.25 % of the radiolabel 
remained in selected tissues (Badger et al., 2002b). 
The results of toxicokinetic studies conducted with isoeugenol administered by gavage or intravenously to 
Fischer 344/N rats and B6C3F1 mice indicate that isoeugenol undergoes extensive first-pass metabolism 
(Fuciarelli, 2001). Isoeugenol was detected in the plasma of rats and mice 2 min after the administration by 
gavage of single doses of 17 and 35 mg/kg bw to rats and mice. The time at which peak plasma 
concentrations (Tmax) were attained was shown to be short, with values ranging from between 2 and 20 min 
in rats, and between 5 and 20 min in mice. Collectively, these data indicate that isoeugenol is rapidly 
absorbed from the gastrointestinal tract. However, the results indicate that isoeugenol has a low 
bioavailability (approximately 14 % for rats at 17 mg/kg bw and approximately 35 % for mice at 35 mg/kg 
bw). On the basis of the low bioavailability, the authors concluded that isoeugenol undergoes extensive  first-
pass metabolism before systemic distribution. Short half-lifes for both species also indicate that isoeugenol is 
rapidly eliminated from the systemic circulation. The high total clearance values reported for rats and mice 
further support the conclusion that isoeugenol is rapidly and extensively eliminated from systemic circulation 
after administration by gavage (Fuciarelli, 2001). 
III.3. Metabolism 
After absorption, orally administered hydroxypropenylbenzene derivatives are completely metabolised in 
humans, rats and mice. Pharmacokinetic and metabolic information on isoeugenol, isoeugenol methyl ether 
and related alkoxypropenylbenzene derivatives (e.g. trans-anethole) indicate that hydroxypropenylbenzenes 
primarily undergo conjugation of the phenolic OH group with sulphate or glucuronic acid, followed by 
excretion mainly in the urine. Dealkylation of ring alkoxy substituents and oxidation of the propenyl side-
chain are minor metabolic pathways for hydroxypropenylbenzene derivatives.  
Isoeugenol, which contains a free phenolic hydroxy group, is also readily conjugated with glucuronic acid 
and sulphate, and subsequently excreted (Williams, 1959a; Badger et al., 2002b). In male Fischer 344 rats, 
given [14C] isoeugenol in a single oral dose of 156 mg/kg bw or a single intravenous dose of 15.6 mg, more 
than 80 % of the administered dose was excreted as the glucuronic acid and sulphate conjugate in the urine 
within 72 hours. With both routes of administration, approximately 10 % of the administered dose was 
excreted in the faeces and < 0.1 % was recovered in expired air (Badger et al., 2002b).  
It is important to note that in contrast to several 2-propenylbenzenes (e.g. safrole, methyleugenol, estragole 
or eugenol) the double bond in isoeugenol is at the 1'-carbon atom of the propenyl side chain, rather than at 
the 2'-position. As a result of the position of the double bond in the 2-propenylbenzenes, these substances 
can be subject to 1'-hydroxylation followed by sulphation. When the sulphate group is subsequently split off 
from the 1'-carbon, a reactive carbocation is formed which is claimed to be responsible for the genotoxicity 
and carcinogenicity of these 2-propenylbenzenes. This mechanism is not possible for isoeugenol or the 
candidate substances, due to the different position of the double bond in the propenyl chain, and therefore no 
concern for genotoxicity and carcinogenicity is raised from the structures of these substances. 
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III.4. Conclusion 
In summary, the major metabolic pathway for isoeugenol and isoeugenyl esters involves rapid conjugation 
with sulphate or glucuronic acid, followed by excretion in the urine. The same metabolic pathway is 
anticipated for the 4-prop-1-enylphenol. Minor metabolic pathways involve the O-dealkylation of ring 
alkoxy substituents, or oxidation of the propenyl side-chain via omega-oxidation or epoxidation. The Panel 
concluded that the candidate substances could be anticipated to be metabolised to innocuous products. 
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ANNEX IV: TOXICITY 
 
ACUTE TOXICITY 
Oral acute toxicity data are not available for the candidate substances of the present Flavouring Group Evaluation, but for four supporting substances 
evaluated by the JECFA at the 61st meeting.  
Table IV.1: Acute Toxicity 
Chemical Name  Species  Sex  Route  LD50 
(mg/kg bw)  
Reference  
(Isoeugenol [04.004]) Rat  M, F Oral  286  (Piccirillo, 1984b) 
Rat  M, F Oral  1560  (Jenner et al., 1964) 
Guinea Pig  M, F Oral  1410  (Jenner et al., 1964) 
(2-Methoxy-4-(prop-1-enyl)phenyl acetate [09.030 ]) Rat  NR Oral  3450  (Moreno, 1973am) 
(6-Ethoxyprop-3-enylphenol [04.002])  Rat  M, F Oral  1575  (Piccirillo, 1984b) 
Rat  NR Oral  2400  (Bär & Griepentrog, 1967) 
(2,6-Dimethxy-4-Prop-1-enylphenol [04.055 ]) Rat  M, F Oral  2400  (Piccirillo & Hartman, 1982) 
M=Male; F=Female; NR=Not Reported. 
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SUBACUTE, SUBCRONIC, CHRONIC AND CARCINOGENIC TOXICITY STUDIES 
Subacute / subchronic / chronic / carcinogenic toxicity data are not available for the candidate substances of the present Flavouring Group Evaluation, but for 
two supporting substances evaluated by the JECFA at the 61st meeting.  
Table IV.2: Subacute / Subchronic / Chronic / Carcinogenicity Studies 
Chemical Name  Species; Sex 
No./Group 
Route  Dose levels 
mg/kg bw 
Duration (days) NOAEL 
(mg/kg/day) 
Reference Comments 
(Isoeugenol [04.004]) Mouse; M, F  
20 
 Gavage  37.5, 75, 150, 300, 600 90 3001  (NTP, 2002b)  
Rat; M, F  
20 
 Gavage  37.5, 75, 150, 300, 600 90 F: 37.51  
M: < 37.51  
(NTP, 2002b)  
Rat; M, F  
10 
 Gavage  1000 112  10002  (Hagan et al., 1967)  
Mouse; M, F  
50 
 Gavage  75, 150, 300 735  75  (NTP, 2010a)  
Rat; M, F  
50 
 Gavage  75, 150, 300 F: 728 
M: 735 
F: 75 
M: < 75 
(NTP, 2010a)  
(6-Ethoxyprop-3-enylphenol [04.002]) Rat; M, F   
20 
 Gavage  250, 1250, 2500  29  250  (Terrill, 1991)  
M=Male; F=Female.  
1 NOEL based on limited information obtained from the National Toxicology Program Preliminary Report.  
2 Study performed with either a single dose or multiple doses that produced no effect.   
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DEVELOPMENTAL AND REPRODUCTIVE TOXICITY STUDIES 
No developmental and reproductive toxicity data are available for the candidate substances of the present Flavouring Group Evaluation. For the supporting 
substance isoeugenol, developmental and reproductive studies are available. The studies were not considered by the JECFA at the 61st meeting. 
Table IV.3: Developmental and Reproductive Toxicity  Studies 
Chemical Name  Species; Sex 
No./Group 
Route  Dose levels 
mg/kg bw/day 
Treatment (days) LOAEL 
mg/kg/day 
NOAEL 
mg/kg bw/day 
Reference Comments 
(Isoeugenol [04.004]) Rat; F  
25 
 Gavage  250, 500 or 
1,000 
Gestational days (GD) 6-
19 
 
Maternal toxicity: 
250  
Developmental 
toxicity: 1,000 
Developmental 
toxicity: 500 
(NTP, 1998);  
(George et al., 2001) 
No resorption or late fetal death.  
At 1,000 mg/kg decreased average 
fetal body weight per litter by 7 % 
(male) and 9 % (female) on GD20.  
At 1,000 mg/kg increased incidence of 
unossified sternebra in fetuses.  
At  250 mg/kg reduced body weight 
and gestational weight gain in dams. 
 
Rat; M, F  
20 
 Gavage  70, 230, 700 Two generations  Reproductive 
toxicity: 230 
(EMEA, 2009) At 700 mg/kg mild reproductive 
toxicity (decrease in the number of F1 
pups per litter and decreases in F2 
male and female pup weights). 
M=Male; F=Female.
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GENOTOXICITY (IN VITRO) 
 
In vitro mutagenicity/genotoxicity data are not available for the candidate substances of the present Flavouring Group Evaluation, but for three supporting 
substances evaluated by the JECFA at the 61st meeting.  
Table IV.4: Genotoxicity (in vitro) 
Chemical Name  Test System Test Object  Concentration Result  Reference  Comments 
(Isoeugenol [04.004]) Reverse Mutation  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538  
 2, 20, and 200 microg/plate  Negative1  (Hsia et al., 1979) Summarised by JECFA 
Reverse Mutation S. typhimurium TA98 and TA100  0.05 to 100 microl/plate  
 (54.1 to 108,200 microg/plate) 
Negative1  (Rockwell & Raw, 1979) Summarised by JECFA 
Reverse Mutation  S. typhimurium TA98, TA100, TA1535, 
TA1537  
 3 micromol/plate  
 (493 microg/plate)   
Negative2   (Florin et al., 1980) Summarised by JECFA 
Reverse Mutation  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538  
 0.8 mg/plate  
 (800 microg/plate)  
Negative2  (Douglas et al., 1980) Summarised by JECFA 
Reverse Mutation  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538  
 60, 120, and 300 microg/plate  Negative2   (Sekizawa & Shibamoto, 
1982) 
Summarised by JECFA 
Reverse Mutation  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538  
 1.0 microl/plate  
 (1,082 microg/plate)  
Negative2   (DeGraff, 1983c) Summarised by JECFA 
Reverse Mutation  S. typhimurium TA97, TA98, TA100,  
TA1535, TA1537  
 Up to 800 microg/plate  Negative2   (Mortelmans et al., 1986) Summarised by JECFA 
Reverse Mutation  S. typhimurium TA97 and TA102   Up to 0.5 mg/plate  
 (500 microg/plate)  
Negative2   (Fujita & Sasaki, 1987)  Summarised by JECFA 
Reverse Mutation  S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538  
 1,000 microg/plate  Negative2   (Heck et al., 1989) Summarised by JECFA 
Point Mutation  E. coli WP2 uvrA   60, 120, and 300 microg/plate  Negative2   (Sekizawa & Shibamoto, 
1982) 
Summarised by JECFA 
DNA Repair B. subtillis H 17 (rec+) and M 45 (rec-)    22.0 microg/disk Negative (Oda et al., 1979) Summarised by JECFA 
DNA Repair B. subtillis H 17 (rec+) and M 45 (rec-)   0.8 mg/disk  
(800 microg/disk)   
Positive3 (Sekizawa & Shibamoto, 
1982) 
Summarised by JECFA 
Sister Chromatid 
Exchange  
Chinese hamster ovary cells  10, 33.3, and 100 microM 
(1.64, 5.47, and 16.42 microg/ml) 
Negative3  (Sasaki et al., 1989) Summarised by JECFA 
Sister Chromatid 
Exchange  
Human Lymphocytes  0.5 mM  
(82 microg/ml)  
Positive (Jansson et al., 1986) Summarised by JECFA 
Unscheduled DNA 
Synthesis  
Mouse Hepatocytes  Up to 1,000 microM  
(164.2 microg/ml) 
Negative (Burkey et al., 2000) Summarised by JECFA 
Unscheduled DNA 
Synthesis  
Rat Hepatocytes  Up to 1,000 microM  
(164.2 microg/ml) 
Negative (Burkey et al., 2000) Summarised by JECFA 
Reverse Mutation S. typhimurium TA98, TA100, TA1535, 
TA1537 
Up to 1,000 microg/plate Negative2  (NTP, 2010a) Summarised by JECFA 
Point Mutation E. coli WP2 uvrA/pKM101 Up to 1,000 microg/plate Negative2  (NTP, 2010a) Summarised by JECFA 
Sister Chromatid 
Exchange 
Chinese hamster ovary cells Up to 200 microg/ml1 
Up to 500 microg/ml3 
Negative2  (NTP, 2010a) Summarised by JECFA 
(Isoeugenyl phenylacetate [09.710]) Reverse Mutation  S. typhimurium TA1535, TA1537, 
TA1538, TA98 and TA100  
 
Up to 3.6 mg/plate  
(3,600 microg/plate)  
Negative2  (Wild et al., 1983) Summarised by JECFA 
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Table IV.4: Genotoxicity (in vitro) 
Chemical Name  Test System Test Object  Concentration Result  Reference  Comments 
(6-Ethoxyprop-3-enylphenol [04.002]) Reverse Mutation  S. typhimurium TA1535, TA1537, 
TA1538, TA98 and TA100  
Up to 3.6 mg/plate  
(3,600 microg/plate)  
Negative2  (Wild et al., 1983) Summarised by JECFA 
(6-Ethoxyprop-3-enylphenol [04.002]) 
cont. 
Reverse Mutation S. typhimurium TA98, TA100, TA1535, 
TA1537, TA1538  
Up to 1,000 microg/plate   Negative2  (Jagannath, 1982) Summarised by JECFA 
      
Forward Mutation   Mouse lymphoma L5178Y TK+/- cells  1.875 to 100 microg/ml   Positive1  (Cifone, 1983) Summarised by JECFA 
Forward Mutation   Mouse lymphoma L5178Y TK+/- cells   7.81 to 125 microg/ml   Negative3  (Cifone, 1983) Summarised by JECFA 
Unscheduled 
DNASynthesis  
 Rat Primary Hepatocytes   1.01 to 50.4 microg/ml   Negative (Cifone, 1988b) Summarised by JECFA 
1 With metabolic activation.  
2 With and without metabolic activation.  
3 Without metabolic activation.  
 
GENOTOXICITY (IN VIVO) 
In vivo mutagenicity/genotoxicity data are not available for the candidate substances of the present Flavouring Group Evaluation, but for two supporting 
substances evaluated by the JECFA at the 61st meeting. Furthermore in vivo data are available for the supporting substance isoeugenol, these data were not 
considered by the JECFA at the 61st meeting. 
Table IV.5: Genotoxicity (in vivo) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
(Isoeugenol [04.004]) Micronucleus Induction in bone 
marrow (OECD No 474) 
Mouse Males  Oral gavage 500,  1000, 2000 mg/kg 
bw one dose 
M: Negative (EMEA, 2009) No increase in the frequency of micronucleated 
polychromatic erythrocytes in treated animals as compared 
to the negative control. 
Study weaknesses:  
Only male mice were used in this test. 
Micronucleus Induction in 
peripheral blood 
B6C3F1 
Mouse Males 
and Females 
Oral gavage  37.5, 75, 150, 300, 600 
mg/kg bw for 3 months 
M: Negative 
F: Positive 
 
(NTP, 2010a) 
 
Frequencies of micronucleated erythrocytes were not 
increased in peripheral blood of male mice exposed to 
isoeugenol by gavage for 3 months; however, an 
increasing trend and a threefold increase in the 600 mg/kg 
group indicate a positive result for this test in female mice. 
Study weaknesses:  
No positive control included,  
historical control data is lacking,  
lack of consistency in the control data sets between sexes,  
data on the ratios of micronucleated normochromatic 
erythrocytes per thousand normochromatic erythrocytes, 
together with their standard errors, appeared to be random.  
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Table IV.5: Genotoxicity (in vivo) 
Chemical Name  Test System Test Object  Route Dose Result  Reference  Comments 
(Isoeugenol [04.004]) cont. 
 
Micronucleus Induction in bone 
marrow 
Mouse Males 
and Females 
Oral gavage  500,  1000, 2000 mg/kg 
bw (males) 
500,  1000, 1500 mg/kg 
bw (females) 
 
(2 doses 24 hours apart) 
M: Negative 
F: Negative 
 
(EMEA, 2009) No statistically significant increases in the frequency of 
micronucleated polychromatic erythrocytes in the treated 
mice as compared with the vehicle group.   Some of the 
female vehicle control animals had an increased 
proportion of PCE. As a consequence of this high control 
value, a decrease of the proportion of PCE (%) was seen in 
the isoeugenol high dosed female group. The values were 
within the historical range. 
In vivo DNA repair (UDS) test  in 
rat hepatocytes 
Rat Males and 
females 
Oral gavage 600,  2000 mg/kg bw 
(males) 
600,  1250 mg/kg bw 
(females) 
 
(2 doses 14 hours apart) 
 
M: Negative 
F: Negative 
 
(EMEA, 2009) No significant increases in the mean (gross) nuclear grain 
count or mean net nuclear grain count at any dose level 
compared to the vehicle control values. 
Wing spot test Drosophila 
melanogaster 
 164 to 2460 mg/l Negative* (EMEA, 2009)  
(6-Ethoxyprop-3-
enylphenol [04.002]) 
Sex Linked Recessive Lethal 
Chromosomes  
Drosophila 
melanogaster  
Oral 10 mM  
(1782 microg/ml)  
Negative   (Wild et al., 1983)  
Micronucleus Induction  Mouse  Intraperitoneally 649, 1298, and 1947 
mg/kg  
Negative  (Wild et al., 1983)  
(Isoeugenyl phenylacetate 
[09.710]) 
Sex Linked Recessive Lethal 
Chromosomes  
Drosophila 
melanogaster  
Oral 25 mM  
(7059 microg/ml) 
Negative   (Wild et al., 1983)  
Micronucleus Induction  Mouse  Intraperiotenally 
twice within a 
24-hour period 
564, 987, and 1410 mg/kg Negative  (Wild et al., 1983)  
M=Male; F=Female. 
* Using both normal bioactivation enzyme systems and increased cytochrome P450-dependent biotranformation capacity. 
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 ABBREVIATIONS 
ADI  Acceptable Daily Intake 
BW  Body Weight 
CAS  Chemical Abstract Service 
CEF Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
Chemical Abstract Service 
CHO  Chinese hamster ovary (cells) 
CoE  Council of Europe 
DNA  Deoxyribonucleic acid 
EC European Commission 
EFFA  European Food and Fragrance Authority 
EFSA  The European Food Safety Authority 
EMEA  The European Medicines Agency 
EU  European Union 
FAO  Food and Agriculture Organization of the United Nations  
FEMA  Flavor and Extract Manufacturers Association 
FGE  Flavouring Group Evaluation  
GD  Gestational Day 
FLAVIS (FL) Flavour Information System (database) 
ID   Identity 
IOFI  International Organization of the Flavour Industry 
IR   Infrared spectroscopy 
JECFA  The Joint FAO/WHO Expert Committee on Food Additives 
LD50  Lethal Dose, 50%; Median lethal dose 
MS  Mass spectrometry 
MSDI  Maximised Survey-derived Daily Intake 
mTAMDI Modified Theoretical Added Maximum Daily Intake 
NAD  Nicotinamide Adenine Dinucleotide  
NADP  Nicotinamide Adenine Dinucleotide Phosphate 
No  Number 
NOAEL No Observed Adverse Effect Level 
NOEL  No Observed Effect Level 
NTP  National Toxicology Program 
OECD  Organisation for Economic Co-operation and Development 
PCE  Polychromatic erythrocyte 
SCE  Sister Chromatid Exchange 
SCF  Scientific Committee on Food 
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SMART  Somatic Mutation and Recombination Test  
TAMDI Theoretical Added Maximum Daily Intake 
UDS  Unscheduled DNA Synthesis  
WHO  World Health Organisation 
